ASH 2022 Conference Coverage
ASH 2022 Phase 3 VITAL Study: Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis Consistent After Adjustment for Key Baseline Variables
By
ASH 2022 Conference Coverage
FEATURING
Morie Gertz
By
ASH 2022 Conference Coverage
FEATURING
Morie Gertz
Login to view comments.
Click here to Login